** Shares of Emergent BioSolutions EBS.N rise 20.1% to $11.05 premarket
** Late on Wednesday, drugmaker raised the lower end of its annual rev. forecast to $1.07 bln from $1.05, while keeping upper end at $1.13 bln
** It also expects a narrower loss of $30 mln to $50 mln for 2024 versus its earlier estimate of $75 mln to $115 mln
** Co's Q3 adj. EPS of $1.37 beat Wall Street estimates of 14 cents - LSEG
** However, EBS' Q3 rev. of $293.8 mln missed estimates of $297.5 mln
** Co also said its smallpox drug Tembexa was included in a clinical trial for mpox led by the Africa Centres for Disease Control and Prevention
** Up to last close, stock has almost quadrupled YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。